Back to Search
Start Over
F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system
- Source :
- Cancer Research, Cancer Research, American Association for Cancer Research, 2008, 68 (23), pp.9845-53. ⟨10.1158/0008-5472.CAN-08-2748⟩, Cancer Research, 2008, 68 (23), pp.9845-53. ⟨10.1158/0008-5472.CAN-08-2748⟩
- Publication Year :
- 2008
- Publisher :
- HAL CCSD, 2008.
-
Abstract
- The polyamine transport system (PTS) is an energy-dependent machinery frequently overactivated in cancer cells with a high demand for polyamines. We have exploited the PTS to selectively deliver a polyamine-containing drug to cancer cells. F14512 combines an epipodophyllotoxin core-targeting topoisomerase II with a spermine moiety introduced as a cell delivery vector. The polyamine tail supports three complementary functions: (a) facilitate formulation of a water-soluble compound, (b) increase DNA binding to reinforce topoisomerase II inhibition, and (c) facilitate selective uptake by tumor cells via the PTS. F14512 is 73-fold more cytotoxic to Chinese hamster ovary cells compared with CHO-MG cells with a reduced PTS activity. A decreased sensitivity of L1210 leukemia cells to F14512 was observed in the presence of putrescine, spermidine, and spermine. In parallel, the spermine moiety considerably enhances the drug-DNA interaction, leading to a reinforced inhibition of topoisomerase II. The spermine tail of F14512 serves as a cell delivery vehicle as well as a DNA anchor, and this property translates at the cellular level into a distinct pharmacologic profile. Twenty-nine human solid or hematologic cell lines were used to characterize the high cytotoxic potential of F14512 (median IC50 of 0.18 μmol/L). Finally, the potent antitumor activity of F14512 in vivo was evidenced with a MX1 human breast tumor xenograft model, with partial and complete tumor regressions. This work supports the clinical development of F14512 as a novel targeted cytotoxic drug and sheds light on the concept of selective delivery of drugs to tumor cells expressing the PTS. [Cancer Res 2008;68(23):9845–53]
- Subjects :
- Cancer Research
Lung Neoplasms
Spermine
chemistry.chemical_compound
Mice
0302 clinical medicine
Drug Delivery Systems
Cricetinae
Neoplasms
Topoisomerase II Inhibitors
Leukemia L1210
Etoposide
Podophyllotoxin
0303 health sciences
biology
Biogenic Polyamines
DNA, Neoplasm
[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences
[SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciences
Oncology
030220 oncology & carcinogenesis
Female
Mice, Nude
Breast Neoplasms
[SDV.CAN]Life Sciences [q-bio]/Cancer
CHO Cells
[SDV.BC]Life Sciences [q-bio]/Cellular Biology
Binding, Competitive
03 medical and health sciences
Epipodophyllotoxin
Cricetulus
[SDV.CAN] Life Sciences [q-bio]/Cancer
Cell Line, Tumor
Animals
Humans
[SDV.BC] Life Sciences [q-bio]/Cellular Biology
030304 developmental biology
Polyamine transport
Topoisomerase
Molecular biology
Xenograft Model Antitumor Assays
Spermidine
DNA Topoisomerases, Type II
chemistry
Cancer cell
Cancer research
biology.protein
Topoisomerase-II Inhibitor
Polyamine
DNA Damage
Subjects
Details
- Language :
- English
- ISSN :
- 00085472 and 15387445
- Database :
- OpenAIRE
- Journal :
- Cancer Research, Cancer Research, American Association for Cancer Research, 2008, 68 (23), pp.9845-53. ⟨10.1158/0008-5472.CAN-08-2748⟩, Cancer Research, 2008, 68 (23), pp.9845-53. ⟨10.1158/0008-5472.CAN-08-2748⟩
- Accession number :
- edsair.doi.dedup.....d2bf593d5751d6a6d5aadb66777615b8
- Full Text :
- https://doi.org/10.1158/0008-5472.CAN-08-2748⟩